Ziccum CEO Ann Gidner presented Ziccum’s robust new mRNA/LNP results, and Scientific Director Fabrice Rose hosted a well-attended poster session at the mRNA Summit.
CEO Ann Gidner delivered a detailed 30-minute presentation to an audience of 50 - 60 mRNA professionals, including a wide range of senior industry executives, at the mRNA-based Therapeutics Summit Europe 2024 conference in Berlin. An active Q&A session at the end of the presentation included many detailed, relevant questions from an engaged audience.
CEO Ann Gidner: “at this Conference the discussion focused more on practical implementation and handling issues. How we can overcome the inherent stability issues with mRNA/LNP was a much larger topic, it was addressed by many speakers. We can help solve those challenges - we have made so much progress in the mRNA field recently with solid, validated data. So our presentation generated keen interest. It was great to be here”.